<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2024-6-61-66</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1667</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Сывороточный кальпротектин при болезни Бехчета</article-title><trans-title-group xml:lang="en"><trans-title>Serum calprotectin in Behcet's disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6685-7670</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нурбаева</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Nurbaeva</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3246-1157</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черкасова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherkasova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3139-8811</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голоева</surname><given-names>Р. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Goloeva</surname><given-names>R. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3552-2522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетняк</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetnyak</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Магомедалиевна Решетняк</p><p>115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Tatyana Magomedalievna Reshetnyak</p><p>34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993</p></bio><email xlink:type="simple">reshetnyak.tatjana@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2024</year></pub-date><volume>18</volume><issue>6</issue><fpage>61</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нурбаева К.С., Черкасова М.В., Голоева Р.Г., Лила А.М., Решетняк Т.М., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Нурбаева К.С., Черкасова М.В., Голоева Р.Г., Лила А.М., Решетняк Т.М.</copyright-holder><copyright-holder xml:lang="en">Nurbaeva K.S., Cherkasova M.V., Goloeva R.G., Lila A.M., Reshetnyak T.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1667">https://mrj.ima-press.net/mrj/article/view/1667</self-uri><abstract><p>Цель работы – оценить уровень сывороточного кальпротектина (КЛП) при болезни Бехчета (ББ).</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 90 пациентов с ББ (35 женщин и 55 мужчин) и 30 здоровых лиц контрольной группы (22 женщины и 8 мужчин). Медиана возраста пациентов с ББ составила 32 [26; 37] года, лиц контрольной группы – 30 [25; 37] лет. Измерение уровня КЛП в сыворотке крови проводилось методом иммуноферментного анализа с использованием набора реагентов Bulhmann Laboratories AG (Швейцария).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Уровень КЛП был статистически значимо выше у больных с ББ по сравнению со здоровыми (медиана 4,08 [2,81; 7,25] против 2,86 [2,15; 3,92] мкг/мл; р=0,003). У 23 (26%) из 90 пациентов с ББ выявлен повышенный уровень КЛП в сыворотке крови. У пациентов с высоким уровнем КЛП чаще регистрировались активный увеит (отношение шансов, ОШ 4,741; p=0,011), пустулез (ОШ 3,41; p=0,044), артрит (ОШ 13,89; p=0,014) и высокая активность ББ (ОШ 3,195; р=0,029). Обнаружена прямая корреляция между уровнем КЛП и индексом активности BDCAF (rs=0,415, p&lt;0,0001), СРБ (rs=0,466, p&lt;0,0001) и СОЭ (rs=0,357, p=0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Уровень сывороточного КЛП повышен у пациентов с ББ и ассоциирован с высокой активностью заболевания, активным увеитом, пустулезом и артритом.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to assess the level of serum calprotectin (CLP) in Behcet's disease (BD).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 90 patients with BD (35 women and 55 men) and 30 healthy controls (22 women and 8 men). The mean age of the BD patients was 32 [26; 37] years, that of the control subjects was 30 [25; 37] years. Serum CLP levels were measured with an enzyme immunoassay using a reagent kit from Bulhmann Laboratories AG (Switzerland). Results and discussion. CLP levels were statistically significantly higher in patients with BD compared to healthy controls (median 4.08 [2.81; 7.25] vs. 2.86 [2.15; 3.92] μg/ml; p=0.003). Elevated serum CLP levels were found in 23 (26%) of the 90 patients with BD. Patients with high CLP levels were more likely to have active uveitis (odds ratio, OR 4.741; p=0.011), pustulosis (OR 3.41; p=0.044), arthritis (OR 13.89; p=0.014) and high BD activity (OR 3.195; p=0.029). A direct correlation was found between CLP level and BDCAF activity index (rs=0.415, p&lt;0.0001), CRP (rs=0.466, p &lt;0.0001) and ESR (rs=0.357, p=0.001).</p></sec><sec><title>Conclusion</title><p>Conclusion. Serum CLP levels are elevated in patients with BD and are associated with high disease activity, active uveitis, pustulosis and arthritis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Бехчета</kwd><kwd>кальпротектин</kwd><kwd>маркеры активности</kwd><kwd>нейтрофилы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Behcet's disease</kwd><kwd>calprotectin</kwd><kwd>activity markers</kwd><kwd>neutrophils</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья подготовлена в рамках фундаментальной научной темы № 122040400024-7.</funding-statement><funding-statement xml:lang="en">The article was prepared within the framework of the basic scientific topic № 122040400024-7.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Лисицына ТА, Алекберова ЗС, Голоева РГ, Давыдова ГА. Болезнь Бехчета: клинические проявления, современные принципы диагностики и терапии. Научно-практическая ревматология. 2019;57(5): 553-563.</mixed-citation><mixed-citation xml:lang="en">Lisitsyna TA, Alekberova ZS, Goloeva RG, Davydova GA. Behcet's disease: clinical manifestations, current principles of diagnosis and therapy. Nauchno-prakticheskaya revmatologiya. 2019;57(5):553-563. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Le Joncour A, Cacoub P, Boulaftali Y, et al. Neutrophil, NETs and Behcet's disease: A review. Clin Immunol. 2023 May;250:109318. doi: 10.1016/j.clim.2023.109318.</mixed-citation><mixed-citation xml:lang="en">Le Joncour A, Cacoub P, Boulaftali Y, et al. Neutrophil, NETs and Behcet's disease: A review. Clin Immunol. 2023 May;250:109318. doi: 10.1016/j.clim.2023.109318.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Нурбаева КС, Лисицына ТА, Лила АМ, Решетняк ТМ. Роль нейтрофилов в патогенезе болезни Бехчета. Современная ревматология. 2022;16(4):74-79. doi: 10.14412/1996-7012-2022-4-74-79.</mixed-citation><mixed-citation xml:lang="en">Nurbaeva KS, Lisitsyna TA, Lila AM, Reshetnyak TM. The role of neutrophils in the pathogenesis of Behcet's disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022;16(4):74-79. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application. Pharmacol Ther. 2016 Nov;167: 120-131. doi: 10.1016/j.pharmthera.2016.07.015.</mixed-citation><mixed-citation xml:lang="en">Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application. Pharmacol Ther. 2016 Nov;167: 120-131. doi: 10.1016/j.pharmthera.2016.07.015.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Saviano A, Migneco A, Brigida M, et al. Serum Calprotectin in the Evalua-tion of Gastrointestinal Diseases: An Ace up Your Sleeve? Medicina (Kaunas). 2024 May 5; 60(5):762. doi: 10.3390/medicina60050762.</mixed-citation><mixed-citation xml:lang="en">Saviano A, Migneco A, Brigida M, et al. Serum Calprotectin in the Evalua-tion of Gastrointestinal Diseases: An Ace up Your Sleeve? Medicina (Kaunas). 2024 May 5; 60(5):762. doi: 10.3390/medicina60050762.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kopec-Medrek M, Widuchowska M, Kucharz EJ. Calprotectin in rheumatic diseases: a review. Reumatologia. 2016;54(6): 306-309. doi: 10.5114/reum.2016.64907. Epub 2016 Dec 30.</mixed-citation><mixed-citation xml:lang="en">Kopec-Medrek M, Widuchowska M, Kucharz EJ. Calprotectin in rheumatic diseases: a review. Reumatologia. 2016;54(6): 306-309. doi: 10.5114/reum.2016.64907. Epub 2016 Dec 30.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021 Oct;70(10):1978-1988. doi: 10.1136/gutjnl-2021-324855.</mixed-citation><mixed-citation xml:lang="en">Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021 Oct;70(10):1978-1988. doi: 10.1136/gutjnl-2021-324855.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Manfredi M, Van Hoovels L, Benucci M, et al. Circulating Calprotectin (cCLP) in autoimmune diseases. Autoimmun Rev. 2023 May;22(5):103295. doi: 10.1016/j.autrev.2023.103295.</mixed-citation><mixed-citation xml:lang="en">Manfredi M, Van Hoovels L, Benucci M, et al. Circulating Calprotectin (cCLP) in autoimmune diseases. Autoimmun Rev. 2023 May;22(5):103295. doi: 10.1016/j.autrev.2023.103295.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Özseker B, Sahin C, Özseker HS, et al. The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behcet's Disease. Dis Markers. 2016;2016:5423043. doi: 10.1155/2016/5423043.</mixed-citation><mixed-citation xml:lang="en">Özseker B, Sahin C, Özseker HS, et al. The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behcet's Disease. Dis Markers. 2016;2016:5423043. doi: 10.1155/2016/5423043.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kim DH, Park Y, Kim B, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behcet's disease. J Gastroenterol Hepatol. 2017 Mar;32(3): 595-601. doi: 10.1111/jgh.13530.</mixed-citation><mixed-citation xml:lang="en">Kim DH, Park Y, Kim B, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behcet's disease. J Gastroenterol Hepatol. 2017 Mar;32(3): 595-601. doi: 10.1111/jgh.13530.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashida M, Miyoshi J, Mitsui T, et al. Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients with Behcet disease. J Gastroenterol Hepatol. 2020 Aug;35(8):1340-1346. doi: 10.1111/jgh.14995.</mixed-citation><mixed-citation xml:lang="en">Hayashida M, Miyoshi J, Mitsui T, et al. Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients with Behcet disease. J Gastroenterol Hepatol. 2020 Aug;35(8):1340-1346. doi: 10.1111/jgh.14995.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Azramezani Kopi T, Shahrokh S, Mirzaei S, et al. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019 Summer;12(3):183-189.</mixed-citation><mixed-citation xml:lang="en">Azramezani Kopi T, Shahrokh S, Mirzaei S, et al. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019 Summer;12(3):183-189.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Alibaz-Oner F, Direskeneli H. Update on the Diagnosis of Behcet's Disease. Diagnostics (Basel). 2022 Dec 23;13(1):41. doi: 10.3390/diagnostics13010041.</mixed-citation><mixed-citation xml:lang="en">Alibaz-Oner F, Direskeneli H. Update on the Diagnosis of Behcet's Disease. Diagnostics (Basel). 2022 Dec 23;13(1):41. doi: 10.3390/diagnostics13010041.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cantarini L, Pucino V, Vitale A, et al. Immunometabolic biomarkers of inflammation in Behcet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens. Clin Exp Immunol. 2016 May;184(2): 197-207. doi: 10.1111/cei.12768.</mixed-citation><mixed-citation xml:lang="en">Cantarini L, Pucino V, Vitale A, et al. Immunometabolic biomarkers of inflammation in Behcet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens. Clin Exp Immunol. 2016 May;184(2): 197-207. doi: 10.1111/cei.12768.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">International Team for the Revision of the International Criteria for Behзet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47. doi: 10.1111/jdv.12107.</mixed-citation><mixed-citation xml:lang="en">International Team for the Revision of the International Criteria for Behзet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47. doi: 10.1111/jdv.12107.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bhakta BB, Brennan P, James TE, et al. Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999 Aug;38(8):728-33. doi: 10.1093/rheumatology/38.8.728.</mixed-citation><mixed-citation xml:lang="en">Bhakta BB, Brennan P, James TE, et al. Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999 Aug;38(8):728-33. doi: 10.1093/rheumatology/38.8.728.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet's disease in Greece. Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S19-26.</mixed-citation><mixed-citation xml:lang="en">Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet's disease in Greece. Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S19-26.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Oktayoglu P, Mete N, Caglayan M, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behcet's disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2015 Apr;75(2):106-12. doi: 10.3109/00365513.2014.984319.</mixed-citation><mixed-citation xml:lang="en">Oktayoglu P, Mete N, Caglayan M, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behcet's disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2015 Apr;75(2):106-12. doi: 10.3109/00365513.2014.984319.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Karada A. Serum Calprotectin and Iron Metabolism Biomarker Levels in Behcet’s Disease. Turkish Journal of Osteoporosis. 2021; 27(3):140–144. doi: 10.4274/tod.galenos.2021.45403.</mixed-citation><mixed-citation xml:lang="en">Karada A. Serum Calprotectin and Iron Metabolism Biomarker Levels in Behcet’s Disease. Turkish Journal of Osteoporosis. 2021; 27(3):140–144. doi: 10.4274/tod.galenos.2021.45403.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Omma A, Sandikci SC, Colak S, et al. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behcet's disease. Postepy Dermatol Alergol. 2018 Dec;35(6):609-613. doi: 10.5114/pdia.2017.71269.</mixed-citation><mixed-citation xml:lang="en">Omma A, Sandikci SC, Colak S, et al. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behcet's disease. Postepy Dermatol Alergol. 2018 Dec;35(6):609-613. doi: 10.5114/pdia.2017.71269.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеева АС. Клиническое значение кальпротектина при ревматических заболеваниях. Научно-практическая ревмато логия. 2018;56(4):494-499.</mixed-citation><mixed-citation xml:lang="en">Avdeeva AS. Clinical significance of calprotectin in rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2018;56(4):494-499. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Inciarte-Mundo J, Frade-Sosa B, Sanmarti R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022 Nov 3;13: 1001025. doi: 10.3389/fimmu.2022.1001025.</mixed-citation><mixed-citation xml:lang="en">Inciarte-Mundo J, Frade-Sosa B, Sanmarti R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022 Nov 3;13: 1001025. doi: 10.3389/fimmu.2022.1001025.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Torgutalp M, Kelesoglu Dincer A, Yayla E, et al. Serum calprotectin levels in behзet’s disease: relationships between disease activity and clinical parameters. Ann Rheum Dis. 2018;77:504.</mixed-citation><mixed-citation xml:lang="en">Torgutalp M, Kelesoglu Dincer A, Yayla E, et al. Serum calprotectin levels in behзet’s disease: relationships between disease activity and clinical parameters. Ann Rheum Dis. 2018;77:504.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Olson JA, Forrester M, Clohessy PA, et al. Calprotectin is raised in endogenous posterior uveitis. Ocul Immunol Inflamm. 1996;4(2): 91-8. doi: 10.3109/09273949609079638.</mixed-citation><mixed-citation xml:lang="en">Olson JA, Forrester M, Clohessy PA, et al. Calprotectin is raised in endogenous posterior uveitis. Ocul Immunol Inflamm. 1996;4(2): 91-8. doi: 10.3109/09273949609079638.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Abd El Meged Nage S, Esmail A. Calprotectin as a Biomarker for Diagnosis and Severity of Acute Noninfectious Anterior Uveitis in Egyptian Patients. Clin Ophthalmol. 2022 Dec 13;16:4109-4120. doi: 10.2147/OPTH.S389780.</mixed-citation><mixed-citation xml:lang="en">Abd El Meged Nage S, Esmail A. Calprotectin as a Biomarker for Diagnosis and Severity of Acute Noninfectious Anterior Uveitis in Egyptian Patients. Clin Ophthalmol. 2022 Dec 13;16:4109-4120. doi: 10.2147/OPTH.S389780.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Song G, Huang J, Deng Y, et al. The Expression of Calprotectin and Factors in TLR4/NF- B/MyD88 Pathway in Patients with Idiopathic Acute Anterior Uveitis. Ocul Immunol Inflamm. 2019;27(7):1144-1148. doi: 10.1080/09273948.2018.1485956.</mixed-citation><mixed-citation xml:lang="en">Song G, Huang J, Deng Y, et al. The Expression of Calprotectin and Factors in TLR4/NF- B/MyD88 Pathway in Patients with Idiopathic Acute Anterior Uveitis. Ocul Immunol Inflamm. 2019;27(7):1144-1148. doi: 10.1080/09273948.2018.1485956.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Jarlborg M, Courvoisier DS, Lamacchia C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020 May 6;22(1):105. doi: 10.1186/s13075-020-02190-3.</mixed-citation><mixed-citation xml:lang="en">Jarlborg M, Courvoisier DS, Lamacchia C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020 May 6;22(1):105. doi: 10.1186/s13075-020-02190-3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ma Y, Fan D, Xu S, et al. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2020 Nov;88:106948. doi: 10.1016/j.intimp.2020.106948.</mixed-citation><mixed-citation xml:lang="en">Ma Y, Fan D, Xu S, et al. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2020 Nov;88:106948. doi: 10.1016/j.intimp.2020.106948.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ometto F, Friso L, Astorri D, et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 2017 Apr;242(8):859-873. doi: 10.1177/1535370216681551. Epub 2016 Jan 1.</mixed-citation><mixed-citation xml:lang="en">Ometto F, Friso L, Astorri D, et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 2017 Apr;242(8):859-873. doi: 10.1177/1535370216681551. Epub 2016 Jan 1.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hurnakova J, Hulejova H, Zavada J, et al. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS One. 2016 Nov 10;11(11):e0165498. doi: 10.1371/journal.pone.0165498.</mixed-citation><mixed-citation xml:lang="en">Hurnakova J, Hulejova H, Zavada J, et al. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS One. 2016 Nov 10;11(11):e0165498. doi: 10.1371/journal.pone.0165498.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
